We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ROL:NYSERollins, Inc. Analysis

Data as of 2026-03-11 - not real-time

$56.28

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Rollins, Inc. is trading around $56.28, well above its DCF-derived fair value of $22.26, reflecting a high valuation with a trailing PE of 51.6x and a price‑to‑book of 19.7x. The stock shows a neutral technical trend, but the 14‑day RSI of 32 suggests it is approaching oversold territory, while the MACD remains bearish and volume is decreasing. Support sits near $55.36 and resistance near $66.14, giving the price a modest upside potential of about 13% to the median analyst target of $66. Fundamentally, the company posted 9.7% revenue growth in FY 2025 and is projected to grow ~9% YoY in 2026‑27, supported by a strong ROE of 38.9% and operating margins above 17%. Cash generation remains solid with free cash flow of roughly $555 million and a dividend yield of 1.3% paid out at a sustainable 62% payout ratio. The business is low‑beta (0.30) and exhibits high volatility (≈ 39% 30‑day), indicating price swings but limited systematic risk.
Analyst sentiment stays bullish, with a consensus “Buy” rating, a median target of $66, and expectations for earnings growth of 10‑12% in the next two years. However, the recent earnings miss and a bearish MACD temper short‑term enthusiasm, while the elevated valuation and sector‑cyclical exposure suggest caution. Overall, the stock offers a modest upside if it can sustain growth and improve technical momentum, but investors should weigh the high price multiples against the strong cash flow and dividend profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near support at $55.36
  • RSI indicating oversold conditions
  • Bearish MACD and decreasing volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent revenue and earnings growth forecasts (~9‑12%)
  • Strong ROE and operating cash flow
  • Analyst median target price offering ~13% upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustainable dividend with 62% payout ratio
  • Low beta indicating defensive characteristics
  • High valuation multiples may limit upside

Key Metrics & Analysis

Financial Health

Revenue Growth9.70%
Profit Margin14.00%
P/E Ratio51.6
ROE38.94%
ROA15.29%
Debt/Equity75.53
P/B Ratio19.7
Op. Cash Flow$678.1M
Free Cash Flow$555.2M

Technical Analysis

TrendNeutral
RSI32.1
Support$55.36
Resistance$66.14
MA 20$60.00
MA 50$61.23
MA 200$58.50
MACDBearish
VolumeDecreasing
Fear & Greed Index76.91

Valuation

Fair Value$22.26
Target Price$63.66
Upside/Downside13.11%
GradeOvervalued
TypeGrowth
Dividend Yield1.30%

Risk Assessment

Beta0.30
Volatility39.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.